Exscientia Completes $100 Million Series C Financing Round with BlackRock Funds
4 Mar 2021
Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company's Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding.
PHESI AND SENSYNE PARTNERSHIP EXPANDS CLINICAL DEVELOPMENT CAPABILITIES AND SOLUTIONS
5 Jan 2021
The investment will be used to accelerate Phesi's and Sensyne's product roadmaps.
Exscientia Receives $4.2M Grant from Bill & Melinda Gates Foundation to Identify New Targets and Leads for Malaria, Tuberculosis, and Non-hormonal Contraception
10 Dec 2020
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
17 Nov 2020
SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need.
Artificial Intelligence
21 Aug 2020
Artificial Intelligence plays a pivotal role in drug discovery. In particular, artificial neural networks, such as deep neural networks (DNN) or recurrent neural networks (RNN) drive the evolution of this area. Owing to its ability to identify meaningful relationships in raw data, AI can be used in multiple medical scenarios.
Join Our Newsletter for Free
